Key Developments: PharMerica Corp (PMC.N)

PMC.N on New York Stock Exchange

14.79USD
1 Aug 2013
Price Change (% chg)

$0.15 (+1.02%)
Prev Close
$14.64
Open
$14.73
Day's High
$14.81
Day's Low
$14.60
Volume
40,975
Avg. Vol
69,219
52-wk High
$16.44
52-wk Low
$9.85

Search Stocks

Latest Key Developments (Source: Significant Developments)

Pharmerica Corp Reaffirms FY 2013 Guidance
Wednesday, 1 May 2013 04:13pm EDT 

Pharmerica Corp reaffirmed fiscal 2013 guidance and expect to deliver strong financial and operational performance throughout the remainder of the year. The Company maintained fiscal 2013 guidance issued on February 7, 2013. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenues of $1.665 billion, EBITDA of $113 million, net income of $41 million and EPS of $1.39 for fiscal 2013.  Full Article

Pharmerica Corp Appoints David Froesel, Jr. as Interim Chief Financial Officer
Friday, 12 Apr 2013 04:05pm EDT 

Pharmerica Corp announced that the Company has appointed David W. Froesel, Jr. as interim Chief Financial Officer, effective immediately. Mr. Froesel succeeds Michael J. Culotta, who by mutual agreement with the Company, is stepping down to pursue other interests.  Full Article

Pharmerica Corp Issues FY 2013 Mixed Guidance
Thursday, 7 Feb 2013 04:11pm EST 

Pharmerica Corp announced that for fiscal 2013, it expects revenues in the range of $1.567-$1.694 billion, adjusted EBITDA in the range of $113.2-$121.2 million, Net income in the range of $37.3-$42.0 million and adjusted diluted earnings per share in the range of $1.39-$1.55. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenues of $1.742 billion, EBITDA of $105.3 million, net income of $38.5 million and EPS of $1.32 for fiscal 2013.  Full Article

Pharmerica Corp Acquires Amerita, Inc
Thursday, 13 Dec 2012 04:15pm EST 

Pharmerica Corp announced that it has acquired Amerita, Inc. in an all cash transaction. Amerita is a provider of specialty home infusion services with operations in Tennessee, Texas, Oklahoma, Colorado and Utah. This transaction is expected to be moderately accretive to the Company in 2013. Terms of the transaction were not disclosed.  Full Article

Pharmerica Corp Narrows FY 2012 Guidance To A Range In Line With Analysts' Estimates
Thursday, 1 Nov 2012 04:00pm EDT 

Pharmerica Corp updated its fiscal 2012 earnings guidance range as follows: revenues in the range of $1.825-$1.835 billion, adjusted EBITDA in the range of $98.0-$102.0 million, net income in the range of $ $34.4-$37.0 million and adjusted diluted earnings per share (EPS) in the range of $1.15-$1.24. Prior guidance for fiscal 2012 is as follows: revenues in the range of $1.815-$1.845 billion, adjusted EBITDA in the range of $93.0-$102.0 million, net income in the range of $ $31.2-$38.0 million and adjusted diluted earnings per share (EPS) in the range of $1.05-$1.28. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenues of $1.835 billion, EBITDA of $100.0 million, net income of $36.1 million and EPS of $1.22 for fiscal 2012.  Full Article

PharMerica Corporation Lowers FY 2012 Revenue Guidance; Reaffirms FY 2012 Earnings Guidance
Thursday, 2 Aug 2012 04:12pm EDT 

PharMerica Corporation announced that for fiscal 2012, it expects revenues of $1.815-$1.845 compared to previous range of $1.915-$1.950 billion, adjusted EBITDA of $93.0-$102.0 million, adjusted net income of $31.0-$37.8 million and adjusted diluted earnings per common share (EPS) of $1.05-$1.28 same as pervious range. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $1.945 billion, EBITDA of $100.6 million, net income of $35.9 million and EPS of $1.21 for fiscal 2012.  Full Article

PharMerica Corporation Announces $25 Million Share Purchase Program
Monday, 2 Jul 2012 04:01pm EDT 

PharMerica Corporation announced that its Board of Directors has authorized an increase in its existing share purchase program that will allow the Company to purchase up to $25 million of its common stock in the open market through unsolicited or solicited privately negotiated transactions, or in such other appropriate manner, and will be funded from available cash. The amount and timing of the purchases will be determined by the Company`s management and will depend on a variety of factors including price, corporate and regulatory requirements, capital availability and other market conditions. Common stock acquired through the share purchase program will be held as treasury shares and may be used for general corporate purposes.  Full Article

PharMerica Corporation Issues FY 2012 Guidance
Thursday, 9 Feb 2012 04:05pm EST 

PharMerica Corporation announced that for fiscal 2012, it expects revenues of $1.915-$1.950 billion, adjusted EBITDA of $93.0-$102.0 million, adjusted net income of $31.0-$37.8 million and adjusted diluted earnings per common share (EPS) of $1.05-$1.28.  Full Article

Omnicare, Inc. Files Amendment To Tender Offer To Acquire PharMerica Corporation
Friday, 16 Dec 2011 08:00am EST 

Omnicare, Inc. announced that it will file an amendment to its Tender Offer Statement on Schedule TO relating to its offer to purchase all outstanding shares of PharMerica Corporation common stock for $15.00 per share in cash. The amendment provides additional background information regarding recent interactions between Omnicare and PharMerica, including a meeting on December 15, 2011 between representatives of Omnicare and PharMerica and their respective financial and legal advisors. While the meeting concluded with the parties tentatively agreeing that they would contact each other on or about January 19, 2012, the meeting resulted in no progress toward an agreement. Also, Omnicare has not been provided access to any additional due diligence material.  Full Article

PharMerica Corporation Lowers High End Of Prior FY 2011 Revenue Guidance To A Range Below Analysts' Estimates; Raises FY 2011 Earnings Guidance
Thursday, 3 Nov 2011 04:11pm EDT 

PharMerica Corporation announced that for fiscal 2011, it expects revenues to be between $2,080-$2,090, compared to previous range of $2,080-$2,110; adjusted EBITDA to be between $90.0-$92.0, compared to previous range of $82.0-$86.0; net income is expected to be between $29.7-$31.2, compared to previous range of $24.9-$27 and adjusted diluted earnings per share (EPS) guidance to a range of $1.01-$1.06 from a range of $0.85-$0.95. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $2.106 billion, EBITDA of $85 million, net income of $27.3 million and EPS of $0.93 for fiscal 2011.  Full Article

Search Stocks